Emerging microtubule targets in glioma therapy

Seminars in Pediatric Neurology

Volumn 22, Issue 1, 2015, Pages 49-72

  Katsetos, Christos D ^a,b   Reginato, Mauricio J ^b   Baas, Peter W ^b   D'Agostino, Luca ^a   Legido, Agustin ^a   Tuszyński, Jack A ^c   Dráberová, Eduarda ^d   Dráber, Pavel ^d  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; BETAIII TUBULIN; COLCHICINE; COMBRETASTATIN A4; EPOTHILONE B; GAMMA TUBULIN; GAMMA TUBULIN COMPLEX PROTEIN; ISPINESIB; IXABEPILONE; KINESIN; NOSCAPINE; SAGOPILONE; SPASTIN; STATHMIN; TAXANE DERIVATIVE; TUBULIN; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RESISTANCE; CELL CYCLE PROGRESSION; CELL MIGRATION; CELLULAR DISTRIBUTION; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; GLIOBLASTOMA; GLIOMA; HUMAN; MICROTUBULE; MITOSIS; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; ARTIFICIAL NEURAL NETWORK; CARCINOGENESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MICROTUBULES; NEURAL NETWORKS (COMPUTER);

EID: 84929174986     PISSN: 10719091     EISSN: 15580776     Source Type: Journal    
DOI: 10.1016/j.spen.2015.03.009     Document Type: Article

References (272)

1. Ohgaki H., Kleihues P. The definition of primary and secondary glioblsastoma. Clin Cancer Res 2013, 19:764-772.
2. Rickert C.H., Sträter R., Kaatsch P., et al. Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am J Pathol 2001, 158:1525-1532.
3. McDonald K.L., Aw G., Kleihues P. Role of biomarkers in the clinical management of glioblastomas: What are the barriers and how can we overcome them?. Front Neurol 2012, 3:188.
4. Louis D.N., Perry A., Burger P., et al. International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014, 24:429-435.
5. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
6. Sathornsumetee S., Rich J.N. Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci 2008, 1142:108-132.
7. Reardon D.A., Rich J.N., Friedman H.S., et al. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006, 24:1253-1265.
8. Hegi M.E., Diserens A.C., Godard S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10:1871-1874.
9. Huse J.T., Holland E.C. Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010, 10:319-331.
10. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010, 10:194-204.
11. Jordan M.A., Wilson L. Microtubules and actin filaments: Dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998, 10:123-130.
12. Pasquier E., Kavallaris M. Microtubules: A dynamic target in cancer therapy. IUBMB Life 2008, 60:165-170.
13. Dumontet C., Jordan M.A. Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010, 9:790-803.
14. Katsetos C.D., Dráber P., Kavallaris M. Targeting βIII-tubulin in glioblastoma multiforme: From cell biology and histopathology to cancer therapeutics. Anticancer Agents Med Chem 2011, 11:719-728.
15. Katsetos C.D., Dráber P. Tubulins as therapeutic targets in cancer: From bench to bedside. Curr Pharm Des 2012, 18:2778-2792.
16. Whipple R.A., Balzer E.M., Cho E.H., et al. Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells. Cancer Res 2008, 68:5678-5688.
17. Schoumacher M., Goldman R.D., Louvard D., et al. Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J Cell Biol 2010, 189:541-556.
18. Stehbens S., Wittmann T. Targeting and transport: How microtubules control focal adhesion dynamics. J Cell Biol 2012, 198:481-489.
19. Fife C.M., McCarroll J.A., Kavallaris M. Movers and shakers: Cell cytoskeleton in cancer metastasis. Br J Pharmacol 2014, 171:5507-5523.
20. Akhshi T.K., Wernike D., Piekny A. Microtubules and actin crosstalk in cell migration and division. Cytoskeleton (Hoboken) 2014, 71:1-23.
21. Pasquier E., Kavallaris M., André N. Metronomic chemotherapy: New rationale for new directions. Nat Rev Clin Oncol 2010, 7:455-465.
22. Parker A.L., Kavallaris M., McCarroll J.A. Microtubules and their role in cellular stress in cancer. Front Oncol 2014, 4:153.
23. Katsetos C.D., Dráberová E., Legido A., et al. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III β-tubulin. J Cell Physiol 2009, 221:505-513.
24. Dráberová E., Dráber P. Microtubules. Cytoskeleton and Human Disease 2012, 29-53. Springer-Verlag, New York, NY. M. Kavallaris (Ed.).
25. McCarroll J.A., Kavallaris M. Microtubules, drug resistance, and tumorigenesis. Cytoskeleton and Human Disease 2012, 223-240. Springer-Verlag, New York, NY. M. Kavallaris (Ed.).
26. Katsetos C.D., Anni H., Dráber P. Mitochondrial dysfunction in gliomas. Semin Pediatr Neurol 2013, 20:216-227.
27. Yount A.L., Zong H., Walczak C.E. Regulatory mechanisms that control mitotic kinesins. Exp Cell Res 2015, pii: S0014-4827(14)00556-4.
28. Nogales E., Wolf S.G., Downing K.H. Structure of the αβ tubulin dimer by electron crystallography. Nature 1998, 391:199-203.
29. Löwe J., Li H., Downing K.H., et al. Refined structure of αβ-tubulin at 3.5 A resolution. J Mol Biol 2001, 313:1045-1057.
30. Nogales E., Whittaker M., Milligan R.A., et al. High-resolution model of the microtubule. Cell 1999, 96:79-88.
31. Li H., DeRosier D.J., Nicholson W.V., et al. Microtubule structure at 8 A resolution. Structure 2002, 10:1317-1328.
32. Downing K.H. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 2000, 16:89-111.
33. Akhmanova A., Steinmetz M.O. Tracking the ends: A dynamic protein network controls the fate of microtubule tips. Nat Rev Mol Cell Biol 2008, 9:309-322.
34. Wang H.W., Nogales E. Nucleotide-dependent bending flexibility of tubulin regulates microtubule assembly. Nature 2005, 435:911-915.
35. Mitchison T., Kirschner M. Dynamic instability of microtubule growth. Nature 1984, 312:237-242.
36. Desai A., Mitchison T.J. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol 1997, 13:83-117.
37. Pollard T.D., Ernshaw W.C. Cell Biology 2008, Saunders-Elsevier, Philadelphia, PA. ed 2.
38. Ludueña R.F. The multiple forms of tubulin: Different gene products and covalent modifications. Int Rev Cytol 1998, 178:207-275.
39. Ludueña R.F., Banerjee A. The isotypes of tubulin: Distribution and functional significance. Cancer Drug Discovery and Development: The Role of Microtubules in Cell Biology, Neurobiology, and Oncology 2008, 123-175. Humana Press, Totowa, NJ. T. Fojo (Ed.).
40. Ludueña R.F. A hypothesis on the origin and evolution of tubulin. Int Rev Cell Mol Biol 2013, 302:41-185.
41. Downing K.H., Nogales E. Tubulin structure: Insights into microtubule properties and functions. Curr Opin Struct Biol 1998, 8:785-791.
42. Bhattacharya R., Cabral F. A ubiquitous β-tubulin disrupts microtubule assembly and inhibits cell proliferation. Mol Biol Cell 2004, 15:3123-3131.
43. Jordan M.A., Kamath K. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 2007, 7:730-742.
44. Linhartová I., Dráber P., Dráberová E., et al. Immunological discrimination of β-tubulin isoforms in developing mouse brain. Post-translational modification of non-class III β-tubulins. Biochem J 1992, 288:919-924.
45. Linhartová I., Dráberová E., Viklický V., et al. Distribution of non-class-III beta-tubulin isoforms in neuronal and non-neuronal cells. FEBS Lett 1993, 320:79-82.
46. Guo J., Walss-Bass C., Ludueña R.F. The β isotypes of tubulin in neuronal differentiation. Cytoskeleton (Hoboken) 2010, 67:431-441.
47. Guo J., Qiang M., Ludueña R.F. The distribution of β-tubulin isotypes in cultured neurons from embryonic, newborn, and adult mouse brains. Brain Res 2011, 1420:8-18.
48. Katsetos C.D., Frankfurter A., Christakos S., et al. Differential localization of class III β-tubulin isotype and calbindin-D28k defines distinct neuronal types in the developing human cerebellar cortex. J Neuropathol Exp Neurol 1993, 52:655-666.
49. Katsetos C.D., Karkavelas G., Herman M.M., et al. Class III β-tubulin isotype (βIII) in the adrenal medulla: I. Localization in the developing human adrenal medulla. Anat Rec 1998, 250:335-343.
50. Dráberová E., Lukáš Z., Ivanyi D., et al. Expression of class III β-tubulin in normal and neoplastic human tissues. Histochem Cell Biol 1998, 109:231-239.
51. Katsetos C.D., Herman M.M., Mörk S.J. Class III β-tubulin in human development and cancer. Cell Motil Cytoskeleton 2003, 55:77-96.
52. Katsetos C.D., Legido A., Perentes E., et al. Class III β-tubulin isotype: A key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. J Child Neurol 2003, 18:851-866.
53. Dráberová E., Del Valle L., Gordon J., et al. Class III β-tubulin is constitutively coexpressed with glial fibrillary acidic protein and nestin in midgestational human fetal astrocytes: Implications for phenotypic identity. J Neuropathol Exp Neurol 2008, 67:341-354.
54. Ludueña R.F., Banerjee A. The post-translational modifications of tubulin. Cancer Drug Discovery and Development: The Role of Microtubules in Cell Biology, Neurobiology, and Oncology 2008, 105-121. Humana Press, Totowa, NJ. T. Fojo (Ed.).
55. Joe P.A., Banerjee A., Ludueña R.F. The roles of cys124 and ser239 in the functional properties of human βIII tubulin. Cell Motil Cytoskeleton 2008, 65:476-486.
56. Khan I.A., Ludueña R.F. Phosphorylation of βIII-tubulin. Biochemistry 1996, 35:3704-3711.
57. Joe P.A., Banerjee A., Ludueña R.F. Roles of β-tubulin residues Ala428 and Thr429 in microtubule formation in vivo. J Biol Chem 2009, 284:4283-4291.
58. Katsetos C.D., Del Valle L., Legido A., et al. On the neuronal/neuroblastic nature of medulloblastomas: A tribute to Pio del Rio Hortega and Moises Polak. Acta Neuropathol 2003, 105:1-13.
59. Katsetos C.D., Kontogeorgos G., Geddes J.F., et al. Differential distribution of the neuron-associated class III β-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med 2000, 124:535-544.
60. Sève P., Dumontet C. Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?. Lancet Oncol 2008, 9:168-175.
61. Azuma K., Sasada T., Kawahara A., et al. Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009, 64:326-333.
62. Levallet G., Bergot E., Antoine M., et al. High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Mol Cancer Ther 2012, 11:1203-1213.
63. Reiman T., Lai R., Veillard A.S., et al. Cross-validation study of class III β-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: Analysis of four randomized trials. Ann Oncol 2012, 23:86-93.
64. Zhang H.L., Ruan L., Zheng L.M., et al. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: A meta-analysis. Lung Cancer 2012, 77:9-15.
65. McCarroll J.A., Gan P.P., Erlich R.B., et al. TUBB3/βIII-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer. Cancer Res 2015, 75:415-425.
66. Kavallaris M., Kuo D.Y., Burkhart C.A., et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997, 100:1282-1293.
67. Mozzetti S., Ferlini C., Concolino P., et al. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005, 11:298-305.
68. Ferrandina G., Zannoni G.F., Martinelli E., et al. Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006, 12:2774-2779.
69. Ferrandina G., Martinelli E., Zannoni G.F., et al. Expression of class III β-tubulin in cervical cancer patients administered preoperative radiochemotherapy: Correlation with response to treatment and clinical outcome. Gynecol Oncol 2007, 104:326-330.
70. Su D., Smith S.M., Preti M., et al. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009, 115:2453-2463.
71. De Donato M., Mariani M., Petrella L., et al. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol 2012, 227:1034-1041.
72. Raspaglio G., Petrillo M., Martinelli E., et al. Sox9 and Hif-2alpha regulate TUBB3 gene expression and affect ovarian cancer aggressiveness. Gene 2014, 542:173-181.
73. Galmarini C.M., Treilleux I., Cardoso F., et al. Class III β-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res 2008, 14:4511-4516.
74. Carles G., Braguer D., Dumontet C., et al. Differentiation of human colon cancer cells changes the expression of β-tubulin isotype and MAPs. Br J Cancer 1999, 80:1162-1168.
75. Urano N., Fujiwara Y., Doki Y., et al. Clinical significance of class III β-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 2006, 28:375-381.
76. Portyanko A., Kovalev P., Gorgun J., et al. βIII-tubulin at the invasive margin of colorectal cancer: Possible link to invasion. Virchows Archiv 2009, 454:541-548.
77. Lee K.M., Cao D., Itami A., et al. Class III β-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology 2007, 51:539-546.
78. McCarroll J.A., Sharbeen G., Liu J., et al. βIII-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer. Oncotarget 2015, 6:2235-2249.
79. Ranganathan S., Salazar H., Benetatos C.A., et al. Immunohistochemical analysis of β-tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy. Prostate 1997, 30:263-268.
80. Terry S., Ploussard G., Allory Y., et al. Increased expression of class III β-tubulin in castration-resistant human prostate cancer. Br J Cancer 2009, 101:951-956.
81. Egevad L., Valdman A., Wiklund N.P., et al. Beta-tubulin III expression in prostate cancer. Scand J Urol Nephrol 2010, 44:371-377.
82. Tsourlakis M.C., Weigand P., Grupp K., et al. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. Am J Pathol 2014, 184:609-617.
83. Quaas A., Rahvar A.H., Burdelski C., et al. βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma. World J Urol 2014, 10.1007/s00345-014-1463-6.
84. Katsetos C.D., Del Valle L., Geddes J.F., et al. Aberrant localization of the neuronal class III β-tubulin in astrocytomas. Arch Pathol Lab Med 2001, 125:613-624.
85. Katsetos C.D., Del Valle L., Geddes J.F., et al. Localization of the neuronal class III β-tubulin in oligodendrogliomas: Comparison with Ki-67 proliferative index and 1p/19q status. J Neuropathol Exp Neurol 2002, 61:307-320.
86. Katsetos C.D., Dráberová E., Šmejkalová B., et al. Class III β-tubulin and γ-tubulin are co-expressed and form complexes in human glioblastoma cells. Neurochem Res 2007, 32:1387-1398.
87. Yan T., Skaftnesmo K.O., Leiss L., et al. Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide. BMC Cancer 2011, 11:524.
88. Mariani M, Karki R, Spennato M, et al. Class III β-tubulin in normal and cancer tissues. Gene pii: S0378-1119(15)00367-4, 2015. http://dx.doi.org/10.1016/j.gene.2015.03.061.
89. Karki R., Mariani M., Andreoli M., et al. βIII-Tubulin: Biomarker of taxane resistance or drug target?. Expert Opin Ther Targets 2013, 17:461-472.
90. Bhattacharya R., Cabral F. Molecular basis for class V β-tubulin effects on microtubule assembly and paclitaxel resistance. J Biol Chem 2009, 284:13023-13032.
91. Verdier-Pinard P., Shahabi S., Wang F., et al. Detection of human βV-tubulin expression in epithelial cancer cell lines by tubulin proteomics. Biochemistry 2005, 44:15858-15870.
92. Hiser L., Aggarwal A., Young R., et al. Comparison of beta-tubulin mRNA and protein levels in 12 human cancer cell lines. Cell Motil Cytoskeleton 2006, 63:41-52.
93. Bhattacharya R., Frankfurter A., Cabral F. A minor β-tubulin essential for mammalian cell proliferation. Cell Motil Cytoskeleton 2008, 65:708-720.
94. Cucchiarelli V., Hiser L., Smith H., et al. Beta-tubulin isotype classes II and V expression patterns in nonsmall cell lung carcinomas. Cell Motil Cytoskeleton 2008, 65:675-685.
95. Gan P.P., Pasquier E., Kavallaris M. Class III β-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007, 67:9356-9363.
96. Gan P.P., Kavallaris M. Tubulin-targeted drug action: Functional significance of class II and class IVb β-tubulin in vinca alkaloid sensitivity. Cancer Res 2008, 68:9817-9824.
97. Akasaka K., Maesawa C., Shibazaki M., et al. Loss of class III β-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells. J Invest Dermatol 2009, 129:1516-1526.
98. McCarroll J.A., Gan P.P., Liu M., et al. βIII-Tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res 2010, 70:4995-5003.
99. Raspaglio G., Filippetti F., Prislei S., et al. Hypoxia induces class III β-tubulin gene expression by HIF- 1α binding to its 3' flanking region. Gene 2008, 409:100-108.
100. Raspaglio G., De Maria I., Filippetti F., et al. HuR regulates β-tubulin isotype expression in ovarian cancer. Cancer Res 2010, 70:5891-5900.
101. Bordji K., Grandval A., Cuhna-Alves L., et al. Hypoxia-inducible factor-2α (HIF-2α), but not HIF-1α, is essential for hypoxic induction of class III β-tubulin expression in human glioblastoma cells. FEBS J 2014, 281:5220-5236.
102. Raspaglio G., Ferrandina G., Ferlini C., et al. Epidermal growth factor-responsive laryngeal squamous cancer cell line Hep2 is more sensitive than unresponsive CO-K3 one to quercetin and tamoxifen apoptotic effects. Oncol Res 2003, 14:83-91.
103. Prislei S., Martinelli E., Mariani M., et al. MiR-200c and HuR in ovarian cancer. BMC Cancer 2013, 13:72.
104. Katsetos C.D., Herman M.M., Frankfurter A., et al. Cerebellar desmoplastic medulloblastomas. A further immunohistochemical characterization of the reticulin-free pale islands. Arch Pathol Lab Med 1989, 113:1019-1029.
105. Katsetos C.D., Krishna L., Frankfurter A., et al. A cytomorphological scheme of differentiating neuronal phenotypes in cerebellar medulloblastomas based on immunolocalization of class III β-tubulin isotype (βIII) and proliferating cell nuclear antigen (PCNA)/cyclin. Clin Neuropathol 1995, 14:72-78.
106. Katsetos C.D., Herman M.M., Frankfurter A., et al. Neuron-associated class III β-tubulin isotype, microtubule-associated protein 2, and synaptophysin in human retinoblastomas in situ. Further immunohistochemical observations on the Flexner-Wintersteiner rosettes. Lab Invest 1991, 64:45-54.
107. Ikota H., Kinjo S., Yokoo H., et al. Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol (Berl) 2006, 111:475-482.
108. Mao Y., Zhou L., Zhu W., et al. Proliferative status of tumor stem cells may be correlated with malignancy grade of human astrocytomas. Front Biosci 2007, 12:2252-2259.
109. Laggner U., Pipp I., Budka H., et al. Immunohistochemical detection of class III beta-tubulin in primary brain tumours: Variable expression in most tumour types limits utility as a differential diagnostic marker. Histopathology 2007, 50:949-952.
110. Martinez-Diaz H., Kleinschmidt-DeMasters B.K., Powell S.Z., et al. Giant cell glioblastoma and pleomorphic xanthoastrocytoma show different immunohistochemical profiles for neuronal antigens and p53 but share reactivity for class III β-tubulin. Arch Pathol Lab Med 2003, 127:1187-1191.
111. Ferlini C., Raspaglio G., Mozzetti S., et al. The seco-taxane IDN5390 is able to target class III β-tubulin and to overcome paclitaxel resistance. Cancer Res 2005, 65:2397-2405.
112. Pepe A., Sun L., Zanardi I., et al. Novel C- seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III β-tubulin. Bioorg Med Chem Lett 2009, 19:3300-3304.
113. Nettles J.H., Li H., Cornett B., et al. The binding mode of epothilone A on α, β-tubulin by electron crystallography. Science 2004, 305:866-869.
114. Dumontet C., Jordan M.A., Lee F.F. Ixabepilone: Targeting βIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009, 8:17-25.
115. Pagano A., Honoré S., Mohan R., et al. Epothilone B inhibits migration of glioblastoma cells by inducing microtubule catastrophes and affecting EB1 accumulation at microtubule plus ends. Biochem Pharmacol 2012, 84:432-443.
116. Henry W.I., Dubois J., Quick Q.A. The microtubule inhibiting agent epothilone B antagonizes glioma cell motility associated with reorganization of the actin-binding protein α-actinin 4. Oncol Rep 2011, 25:887-893.
117. Ferrandina G., Mariani M., Andreoli M., et al. Novel drugs targeting microtubules: The role of epothilones. Curr Pharm Des 2012, 18:2793-2803.
118. Mozzetti S., Iantomasi R., De Maria I., et al. Molecular mechanisms of patupilone resistance. Cancer Res 2008, 68:10197-11204.
119. Colombo N., Kutarska E., Dimopoulos M., et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012, 30:3841-3847.
120. Oehler C., Frei K., Rushing E.J., et al. Patupilone (epothilone B) for recurrent glioblastoma: Clinical outcome and translational analysis of a single-institution phase I/II trial. Oncology 2012, 83:1-9.
121. Oehler C., von Bueren A.O., Furmanova P., et al. The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells. Neuro Oncol 2011, 13:1000-1010.
122. Hoffmann J., Fichtner I., Lemm M., et al. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol 2009, 11:158-166.
123. Silvani A., Gaviani P., Fiumani A., et al. Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. J Neurooncol 2009, 95:61-64.
124. Stupp R., Tosoni A., Bromberg J.E., et al. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann Oncol 2011, 22:2144-2149.
125. Peereboom D.M., Supko J.G., Carson K.A., et al. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. J Neurooncol 2010, 100:261-268.
126. Persico M., Petrella L., Orteca N., et al. GTP is an allosteric modulator of the interaction between the guanylate-binding protein 1 and the prosurvival kinase PIM1. Eur J Med Chem 2015, 91:132-144.
127. Andreoli M., Persico M., Kumar A., et al. Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells. J Med Chem 2014, 57:7916-7932.
128. Yang W., Wei J., Guo T., et al. Knockdown of miR-210 decreases hypoxic glioma stem cells stemness and radioresistance. Exp Cell Res 2014, 326:22-35.
129. Oakley C.E., Oakley B.R. Identification of γ-tubulin, a new member of the tubulin superfamily encoded by mipA gene of Aspergillus nidulans. Nature 1989, 338:662-664.
130. Stearns T., Evans L., Kirschner M. γ-Tubulin is highly conserved component of the centrosome. Cell 1991, 65:825-836.
131. Lajoie-Mazenc I., Tollon I., Détraves C., et al. Recruitment of antigenic gamma-tubulin during mitosis in animal cells: Presence of gamma-tubulin in the mitotic spindle. J Cell Sci 1994, 107:2825-2837.
132. Nováková M., Dráberová E., Schürmann W., et al. γ-Tubulin redistribution in taxol-treated mitotic cells probed by monoclonal antibodies. Cell Motil Cytoskeleton 1996, 33:38-51.
133. Julian M., Tollon Y., Lajoie-Mazenc I., et al. γ-Tubulin participates in the formation of midbody during cytokinesis in mammalian cells. J Cell Sci 1993, 105:145-156.
134. Murphy S.M., Urbani L., Stearns T. The mammalian γ-tubulin complex contains homologues of the yeast spindle pole body components Spc97p and Spc98p. J Cell Biol 1998, 141:663-674.
135. Oegema K., Wiese C., Martin O.C., et al. Characterization of two related Drosophila γ-tubulin complexes that differ in their ability to nucleate microtubules. J Cell Biol 1999, 144:721-733.
136. Wiese C., Zheng Y. A new function for the γ-tubulin ring complex as a microtubule minus-end cap. Nat Cell Biol 2000, 2:358-364.
137. Raynaud-Messina B., Merdes A. Gamma-tubulin complexes and microtubule organization. Curr Opin Cell Biol 2007, 19:24-30.
138. Chabin-Brion K., Marceiller J., Perez F., et al. The Golgi complex is a microtubule-organizing organelle. Mol Biol Cell 2001, 12:2047-2060.
139. Dryková D., Sulimenko V., Cenklová V., et al. Plant γ-tubulin interacts with αβ-tubulin dimers and forms membrane-associated complexes. Plant Cell 2003, 15:465-480.
140. Efimov A., Kharitonov A., Efimova N., et al. Asymmetric CLASP-dependent nucleation of noncentrosomal microtubules at the trans-Golgi network. Dev Cell 2007, 12:917-930.
141. Macurek L., Dráberová E., Richterová V., et al. Regulation of microtubule nucleation in differentiating embryonal carcinoma cells by complexes of membrane-bound γ-tubulin with Fyn kinase and phosphoinositide 3-kinase. Biochem J 2008, 416:421-430.
142. Kollman J.M., Merdes A., Mourey L., et al. Microtubule nucleation by γ-tubulin complexes. Nat Rev Mol Cell Biol 2011, 12:709-721.
143. Teixido-Travesa N., Roig J., Lüders J. The where, when and how of microtubule nucleation-One ring to rule them all. J Cell Sci 2012, 125:4445-4456.
144. Choi Y.K., Liu P., Sze S.K., et al. CDK5RAP2 stimulates microtubule nucleation by the γ-tubulin ring complex. J Cell Biol 2010, 191:1089-1095.
145. Hořejší B., Vinopal S., Sládková V., et al. Nuclear γ-tubulin associates with nucleoli and interacts with tumor suppressor protein C53. J Cell Physiol 2012, 227:367-382.
146. Höög G., Zarrizi R., von Stedingk K., et al. Nuclear localization of γ-tubulin affects E2F transcriptional activity and S-phase progression. FASEB J 2011, 25:3815-3827.
147. Wise D.O., Krahe R., Oakley B.R. The γ-tubulin gene family in humans. Genomics 2000, 67:164-170.
148. Vinopal S., Černohorská M., Sulimenko V., et al. γ-Tubulin 2 nucleates microtubules and is downregulated in mouse early embryogenesis. PLoS One 2012, 7:e29919.
149. Yuba-Kubo A., Kubo A., Hata M., et al. Gene knockout analysis of two γ-tubulin isoforms in mice. Dev Biol 2005, 282:361-373.
150. Katsetos C.D., Dráberová E., Legido A., et al. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. II. γ-Tubulin. J Cell Physiol 2009, 221:514-520.
151. Liu T., Niu Y., Yu Y., et al. Increased γ-tubulin expression and P16INK4A promoter methylation occur together in preinvasive lesions and carcinomas of the breast. Ann Oncol 2009, 20:441-448.
152. Niu Y., Liu T., Tse G.M., et al. Increased expression of centrosomal alpha, gamma-tubulin in atypical ductal hyperplasia and carcinoma of the breast. Cancer Sci 2009, 100:580-587.
153. Katsetos C.D., Reddy G., Dráberová E., et al. Altered cellular distribution and subcellular sorting of γ-tubulin in astrocytic gliomas and human glioblastoma cell lines. J Neuropathol Exp Neurol 2006, 65:465-477.
154. Loh J.K., Lieu A.S., Chou C.H., et al. Differential expression of centrosomal proteins at different stages of human glioma. BMC Cancer 2010, 10:268.
155. Loh J.K., Lieu A.S., Chou C.H., et al. Differential expression of centrosome-associated proteins in human brain tumors: A possible role of hNinein isoform 6 in cell differentiation. Biofactors 2012, 38:470-477.
156. Rickman D.S., Bobek M.P., Misek D.E., et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 2001, 61:6885-6891.
157. Caracciolo V., D'Agostino L., Dráberová E., et al. Differential expression and cellular distribution of γ-tubulin and βIII-tubulin in medulloblastomas and human medulloblastoma cell lines. J Cell Physiol 2010, 223:519-529.
158. Syed M.I., Syed S., Minty F., et al. Gamma tubulin: A promising indicator of recurrence in squamous cell carcinoma of the larynx. Otolaryngol Head Neck Surg 2009, 140:498-504.
159. Maounis N.F., Dráberová E., Mahera E., et al. Overexpression of γ-tubulin in non-small cell lung cancer. Histol Histopathol 2012, 27:1183-1194.
160. Tsai H.P., Tsai C.Y., Lieu A.S., et al. Association of Aurora A and γ-tubulin expression in astrocytomas and patient survival. Neurol Res 2014, 36:746-751.
161. Katsetos C.D., Dráberová E., D'Agostino L., et al. Overexpression of human γ-tubulin small complex proteins GCP2 and GCP3 in glioblastomas and human glioblastoma cell lines. Hell J Nucl Med 2014, 17:82. (suppl) [abstract].
162. Godinho SA, Pellman D. Causes and consequences of centrosome abnormalities in cancer, Phil TransTrans R Soc B 369(1650), pii: 20130467, 2014.
163. Godinho S.A., Picone R., Burute M., et al. Oncogene-like induction of cellular invasion from centrosome amplification. Nature 2014, 510:167-171.
164. Olmsted Z.T., Colliver A.G., Riehlman T.D., et al. Kinesin-14 and kinesin-5 antagonistically regulate microtubule nucleation by γ-TuRC in yeast and human cells. Nat Commun 2014, 5:5339.
165. Linhartová I., Novotná B., Sulimenko V., et al. Gamma-tubulin in chicken erythrocytes: Changes in localization during cell differentiation and characterization of cytoplasmic complexes. Dev Dyn 2002, 223:229-240.
166. Moudjou M., Bordes N., Paintrand M., et al. γ-Tubulin in mammalian cells: The centrosomal and the cytosolic forms. J Cell Sci 1996, 109:875-887.
167. Sulimenko V., Sulimenko T., Poznanovic S., et al. Association of brain γ-tubulins with αβ-tubulin dimers. Biochem J 2002, 365:889-895.
168. Kukharskyy V., Sulimenko V., Macůrek L., et al. Complexes of γ-tubulin with non-receptor protein tyrosine kinases Src and Fyn in differentiating P19 embryonal carcinoma cells. Exp Cell Res 2004, 298:218-228.
169. Stumpff J., Kellogg D.R., Krohne K.A., et al. Drosophila Wee1 interacts with members of the γTURC and is required for proper mitotic-spindle morphogenesis and positioning. Curr Biol 2005, 15:1525-1534.
170. Vogel J., Drapkin B., Oomen J., et al. Phosphorylation of γ-tubulin regulates microtubule organization in budding yeast. Dev Cell 2001, 1:621-631.
171. Starita L.M., Machida Y., Sankaran S., et al. BRCA1-dependent ubiquitination of γ-tubulin regulates centrosome number. Mol Cell Biol 2004, 24:8457-8466.
172. Dráberová L., Dráberová E., Surviladze Z., et al. Protein tyrosine kinase p53/p56(lyn) forms complexes with gamma-tubulin in rat basophilic leukemia cells. Int Immunol 1999, 11:1829-1839.
173. Sulimenko V., Dráberová E., Sulimenko T., et al. Regulation of microtubule formation in activated mast cells by complexes of gamma-tubulin with Fyn and Syk kinases. J Immunol 2006, 176:7243-7253.
174. Remy M.H., Merdes A., Gregory-Pauron L. Assembly of γ-tubulin ring complexes: Implications for cell biology and disease. Prog Mol Biol Transl Sci 2013, 117:511-530.
175. Sulimenko V., Hájková Z., Černohorská M., et al. Microtubule nucleation in mouse bone-marrow derived mast cells is regulated by concerted action of GIT1/βPIX proteins and calcium. J Immunol 2015, 194. 10.4049/jimmunol.1402459.
176. Höland K., Salm F., Arcaro A. The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors. Curr Cancer Drug Targets 2011, 11:894-918.
177. Gaspar N., Marshall L., Perryman L., et al. MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res 2010, 70:9243-9252.
178. Gil del Alcazar C.R., Hardebeck M.C., Mukherjee B., et al. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res 2014, 20:1235-1248.
179. Fenton T.R., Nathanson D., Ponte de A.C., et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci U S A 2012, 109:14164-14169.
180. Feng H., Hu B., Jarzynka M.J., et al. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proc Natl Acad Sci U S A 2012, 109:3018-3023.
181. Portnow J., Badie B., Markel S., et al. A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas. Eur J Cancer 2013, 49:1634-1640.
182. Ehlén A., Rosselló C.A., von S.K., et al. Tumors with nonfunctional retinoblastoma protein are killed by reduced γ-tubulin levels. J Biol Chem 2012, 287:17241-17247.
183. Nayak T., Edgerton-Morgan H., Horio T., et al. Gamma-tubulin regulates the anaphase-promoting complex/cyclosome during interphase. J Cell Biol 2010, 190:317-330.
184. Jiang H., Luo S., Li H. Cdk5 activator-binding protein C53 regulates apoptosis induced by genotoxic stress via modulating the G2/M DNA damage checkpoint. J Biol Chem 2005, 280:20651-20659.
185. Haren L., Remy M.H., Bazin I., et al. NEDD1-dependent recruitment of the gamma-tubulin ring complex to the centrosome is necessary for centriole duplication and spindle assembly. J Cell Biol 2006, 172:505-515.
186. Bouissou A., Verollet C., Sousa A., et al. γ-Tubulin ring complexes regulate microtubule plus end dynamics. J Cell Biol 2009, 187:327-334.
187. Whitehurst A.W., Bodemann B.O., Cardenas J., et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007, 446:815-819.
188. Friesen D., Barakat K.H., Semenchenko V., et al. Discovery of small molecule inhibitors that interact with γ tubulin. Chem Biol Drug Des 2012, 79:639-652.
189. Cala O., Remy M.H., Guillet V., et al. Virtual and biophysical screening targeting the γ-tubulin complex-A new target for the inhibition of microtubule nucleation. PLoS One 2013, 8:e63908.
190. Suri C., Joshi H.C., Naik P.K. Molecular modeling reveals binding interface of γ-tubulin with GCP4 and interactions with noscapinoids. Proteins 2015, [PMID: 25662919]. 10.1002/prot.24773.
191. Lopus M., Naik P.K. Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics. Pharmacol Rep 2015, 67:56-62.
192. Landen J.W., Hau V., Wang M., et al. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res 2004, 10:5187-5201.
193. Newcomb E.W., Lukyanov Y., Alonso-Basanta M., et al. Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors. Int J Radiat Oncol Biol Phys 2008, 71:1477-1484.
194. Wehenkel A., Janke C. Towards elucidating the tubulin code. Nat Cell Biol 2014, 16:303-305.
195. Wolff A., Denoulet P., Jeantet C. High level of tubulin microheterogeneity in the mouse brain. Neurosci Lett 1982, 31:323-328.
196. Wloga D., Gaertig J. Post-translational modifications of microtubules. J Cell Sci 2010, 123:3447-3455.
197. Dráberová E., Viklický V., Dráber P. Exposure of lumenal microtubule sites after mild fixation. Eur J Cell Biol 2000, 79:982-985.
198. Janke C., Bulinski J.C. Post-translational regulation of the microtubule cytoskeleton: Mechanisms and functions. Nat Rev Mol Cell Biol 2011, 12:773-786.
199. Westermann S., Weber K. Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol 2003, 4:938-947.
200. Verhey K.J., Gaertig J. The tubulin code. Cell Cycle 2007, 6:2152-2160.
201. Verdier-Pinard P., Pasquier E., Xiao H., et al. Tubulin proteomics: Towards breaking the code. Anal Biochem 2009, 384:197-206.
202. Palazzo A.F., Eng C.H., Schlaepfer D.D., et al. Localized stabilization of microtubules by integrin- and FAK-facilitated Rho signaling. Science 2004, 303:836-839.
203. Janke C., Rogowski K., van D.J. Polyglutamylation: A fine-regulator of protein function?. EMBO Rep 2008, 9:636-641.
204. Lacroix B., van D.J., Gold N.D., et al. Tubulin polyglutamylation stimulates spastin-mediated microtubule severing. J Cell Biol 2010, 189:945-954.
205. Sirajuddin M., Rice L.M., Vale R.D. Regulation of microtubule motors by tubulin isotypes and post-translational modifications. Nat Cell Biol 2014, 16:335-344.
206. Cai D., McEwen D.P., Martens J.R., et al. Single molecule imaging reveals differences in microtubule track selection between kinesin motors. PLoS Biol 2009, 7:e1000216.
207. Das V., Kanakkanthara A., Chan A., et al. Potential role of tubulin tyrosine ligase-like enzymes in tumorigenesis and cancer cell resistance. Cancer Lett 2014, 350:1-4.
208. Perdiz D., Mackeh R., Poüs C., et al. The ins and outs of tubulin acetylation: More than just a post-translational modification?. Cell Signal 2011, 23:763-771.
209. Bertos N.R., Gilquin B., Chan G.K., et al. Role of the tetradecapeptide repeat domain of human histone deacetylase 6 in cytoplasmic retention. J Biol Chem 2004, 279:48246-48254.
210. Hubbert C., Guardiola A., Shao R., et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417:455-458.
211. Zhang Y., Li N., Caron C., et al. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 2003, 22:1168-1179.
212. Tran A.D., Marmo T.P., Salam A.A., et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci 2007, 120:1469-1479.
213. Suzuki J., Chen Y.Y., Scott G.K., et al. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res 2009, 15:3163-3171.
214. Ninios Y.P., Sekeri-Pataryas K.E., Sourlingas T.G. Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A. Leuk Res 2010, 34:786-792.
215. Barker C.A., Bishop A.J., Chang M., et al. Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 2013, 86:504-509.
216. Cornago M., Garcia-Alberich C., Blasco-Angulo N., et al. Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. Cell Death Dis 2014, e1435.
217. Dal Piaz F., Vassallo A., Lepore L., et al. Sesterterpenes as tubulin tyrosine ligase inhibitors. First insight of structure-activity relationships and discovery of new lead. J Med Chem 2009, 52:3814-3828.
218. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27:5459-5468.
219. Welburn J.P. The molecular basis for kinesin functional specificity during mitosis. Cytoskeleton (Hoboken) 2013, 70:476-493.
220. van Heesbeen R.G., Tanenbaum M.E., Medema R.H. Balanced activity of three mitotic motors is required for bipolar spindle assembly and chromosome segregation. Cell Rep 2014, 8:948-956.
221. Rath O., Kozielski F. Kinesins and cancer. Nat Rev Cancer 2012, 12:527-539.
222. Atherton J., Farabella I., Yu I.M., et al. Conserved mechanisms of microtubule-stimulated ADP release, ATP binding, and force generation in transport kinesins. Elife 2014, e03680.
223. Goulet A., Major J., Jun Y., et al. Comprehensive structural model of the mechanochemical cycle of a mitotic motor highlights molecular adaptations in the kinesin family. Proc Natl Acad Sci U S A 2014, 111:1837-1842.
224. Kahn O., Baas P. Inhibitors of mitotic kinesins for cancer treatment: Consequences for neurons. Kinesins and Cancer 2015, 251-267. Springer, Netherlands. F. Kozielski (Ed.).
225. Exertier P., Javerzat S., Wang B., et al. Impaired angiogenesis and tumor development by inhibition of the mitotic kinesin Eg5. Oncotarget 2013, 4:2302-2316.
226. Müller C., Gross D., Sarli V., et al. Inhibitors of kinesin Eg5: Antiproliferative activity of monastrol analogues against human glioblastoma cells. Cancer Chemother Pharmacol 2007, 59:157-164.
227. Valensin S., Ghiron C., Lamanna C., et al. KiF11 inhibition for glioblastoma treatment: Reason to hope or a struggle with the brain?. BMC Cancer 2009, 9:196.
228. Carol H., Lock R., Houghton P.J., et al. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer 2009, 53:1255-1263.
229. Stuepp C.S., Figueiró F., Mendes F.B., et al. Activity of LaSOM 65, a monastrol-derived compound, against glioblastoma multiforme cell lines. Anticancer Res 2013, 33:4463-4468.
230. Figueiró F., Mendes F.B., Corbelini P.F., et al. A monastrol-derived compound, LaSOM 63, inhibits ecto-5'nucleotidase/CD73 activity and induces apoptotic cell death of glioma cell lines. Anticancer Res 2014, 34:1837-1842.
231. Matsuda M., Yamamoto T., Matsumura A., et al. Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope. Gene Ther 2009, 16:1465-1476.
232. Bie L., Zhao G., Wang Y.P., et al. Kinesin family member 2C (KIF2C/MCAK) is a novel marker for prognosis in human gliomas. Clin Neurol Neurosurg 2012, 114:356-360.
233. Wang Q., Wang L., Li D., et al. Kinesin family member 14 is a candidate prognostic marker for outcome of glioma patients. Cancer Epidemiol 2013, 37:79-84.
234. Takahashi S., Fusaki N., Ohta S., et al. Downregulation of KIF23 suppresses glioma proliferation. J Neurooncol 2012, 106:519-529.
235. Li B., Qi X.Q., Chen X., et al. Expression of targeting protein for Xenopus kinesin-like protein 2 is associated with progression of human malignant astrocytoma. Brain Res 2010, 1352:200-207.
236. Tang N.H., Toda T. MAPping the Ndc80 loop in cancer: A possible link between Ndc80/Hec1 overproduction and cancer formation. Bioessays 2015, 37:248-256.
237. Baas P.W., Ahmad F.J. Beyond taxol: Microtubule-based treatment of disease and injury of the nervous system. Brain 2013, 136:2937-2951.
238. Zhang D., Rogers G.C., Buster D.W., et al. Three microtubule severing enzymes contribute to the "Pacman-flux" machinery that moves chromosomes. J Cell Biol 2007, 177:231-242.
239. Vale R.D. Severing of stable microtubules by a mitotically activated protein in Xenopus egg extracts. Cell 1991, 64:827-839.
240. McNally F.J., Thomas S. Katanin is responsible for the M-phase microtubule-severing activity in Xenopus eggs. Mol Biol Cell 1998, 9:1847-1861.
241. Solowska J.M., D'Rozario M., Jean D.C., et al. Pathogenic mutation of spastin has gain-of-function effects on microtubule dynamics. J Neurosci 2014, 34:1856-1867.
242. Roll-Mecak A., McNally F.J. Microtubule-severing enzymes. Curr Opin Cell Biol 2010, 22:96-103.
243. Dráberová E., Vinopal S., Morfini G., et al. Microtubule-severing ATPase spastin in glioblastoma: Increased expression in human glioblastoma cell lines and inverse roles in cell motility and proliferation. J Neuropathol Exp Neurol 2011, 70:811-826.
244. Zhang D., Grode K.D., Stewman S.F., et al. Drosophila katanin is a microtubule depolymerase that regulates cortical-microtubule plus-end interactions and cell migration. Nat Cell Biol 2011, 13:361-369.
245. Baas P.W., Sharma V. Cell migration: Katanin gives microtubules a trim. Curr Biol 2011, 21:R302-R304.
246. Janke C., Rogowski K., Wloga D., et al. Tubulin polyglutamylase enzymes are members of the TTL domain protein family. Science 2005, 308:1758-1762.
247. Liu Y., Garnham C.P., Roll-Mecak A., et al. Phosphinic acid-based inhibitors of tubulin polyglutamylases. Bioorg Med Chem Lett 2013, 23:4408-4412.
248. Ikegami K., Mukai M., Tsuchida J., et al. TTLL7 is a mammalian beta-tubulin polyglutamylase required for growth of MAP2-positive neurites. J Biol Chem 2006, 281:30707-30716.
249. Laine A.L., Huynh N.T., Clavreul A., et al. Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules. Eur J Pharm Biopharm 2012, 81:690-693.
250. Bocquet A., Berges R., Frank R., et al. Neurofilaments bind tubulin and modulate its polymerization. J Neurosci 2009, 29:11043-11054.
251. Berges R., Balzeau J., Peterson A.C., et al. A tubulin binding peptide targets glioma cells disrupting their microtubules, blocking migration, and inducing apoptosis. Mol Ther 2012, 20:1367-1377.
252. Lépinoux-Chambaud C., Eyer J. The NFL-TBS.40-63 anti-glioblastoma peptide enters selectively in glioma cells by endocytosis. Int J Pharm 2013, 454:738-747.
253. Kuo M.F., Wang H.S., Kuo Q.T., et al. High expression of stathmin protein predicts a fulminant course in medulloblastoma. J Neurosurg Pediatr 2009, 4:74-80.
254. Niethammer P., Bastiaens P., Karsenti E. Stathmin-tubulin interaction gradients in motile and mitotic cells. Science 2004, 303:1862-1866.
255. Wittmann T., Bokoch G.M., Waterman-Storer C.M. Regulation of microtubule destabilizing activity of Op18/stathmin downstream of Rac1. J Biol Chem 2004, 279:6196-6203.
256. Baldassarre G., Belletti B., Nicoloso M.S., et al. p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005, 7:51-63.
257. Hailat N., Strahler J., Melhem R., et al. N-myc gene amplification in neuroblastoma is associated with altered phosphorylation of a proliferation related polypeptide (Op18). Oncogene 1990, 5:1615-6188.
258. Byrne F.L., Yang L., Phillips P.A., et al. RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model. Oncogene 2014, 33:882-890.
259. Song Y., Mu L., Han X., et al. MicroRNA-9 inhibits vasculogenic mimicry of glioma cell lines by suppressing Stathmin expression. J Neurooncol 2013, 115:381-390.
260. Song Y., Mu L., Han X., et al. siRNA targeting stathmin inhibits invasion and enhances chemotherapy sensitivity of stem cells derived from glioma cell lines. Acta Biochim Biophys Sin (Shanghai) 2014, 46:1034-1040.
261. Schiappacassi M., Lovat F., Canzonieri V., et al. p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis. Mol Cancer Ther 2008, 7:1164-1175.
262. Dong B., Mu L., Qin X., et al. Stathmin expression in glioma-derived microvascular endothelial cells: A novel therapeutic target. Oncol Rep 2012, 27:714-718.
263. Wang R., Wang Z., Yang J., et al. LRRC4 inhibits the proliferation of human glioma cells by modulating the expression of STMN1 and microtubule polymerization. J Cell Biochem 2011, 112:3621-3629.
264. Ngo T.T., Peng T., Liang X.J., et al. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst 2007, 99:639-652.
265. Liang X.J., Choi Y., Sackett D.L., et al. Nitrosoureas inhibit the stathmin-mediated migration and invasion of malignant glioma cells. Cancer Res 2008, 68:5267-5272.
266. Zhang T., Zaal K.J., Sheridan J., et al. Microtubule plus-end binding protein EB1 is necessary for muscle cell differentiation, elongation and fusion. J Cell Sci 2009, 122:1401-1409.
267. Molina A., Velot L., Ghouinem L., et al. ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics. Cancer Res 2013, 73:2905-2915.
268. Rodrigues-Ferreira S., Di Tommaso A., Dimitrov A., et al. 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis. PLoS One 2009, 4:e7239.
269. Rovini A., Gauthier G., Bergès R., et al. Anti-migratory effect of vinflunine in endothelial and glioblastoma cells is associated with changes in EB1 C-terminal detyrosinated/tyrosinated status. PLoS One 2013, 8:e65694.
270. Gan P.P., McCarroll J.A., Po'uha S.T., et al. Microtubule dynamics, mitotic arrest, and apoptosis: Drug-induced differential effects of βIII-tubulin. Mol Cancer Ther 2010, 9:1339-1348.
271. Gan P.P., McCarroll J.A., Byrne F.L., et al. Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. PLoS One 2011, 6:e21717.
272. Mitic G, Tsoli M, Ziegler DS, et al.: βIII-Tubulin in Glioblastoma: An Emerging Multifactorial Survival Factor Role in Chemotherapy Response and Tumor Formation. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research, April 6-10, 2013, Washington, DC. Philadelphia (PA), AACR, 2013 [abstract nο. 3431].